The recent regulatory approval and advancement of therapies that focus on restoration of SMN protein have provided meaningful benefit to individuals with SMA and are changing the landscape and outlook for people with SMA (18,20,26,27,33,34). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.